Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
04 oct. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...
aTyr Pharma Announces Research Study with Stanford Medicine
30 juil. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
30 avr. 2024 06h05 HE
|
IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
Glioma Treatment Market worth $8.29 Billion by 2030 - Exclusive Report by The Insight Partners
22 sept. 2023 08h54 HE
|
The Insight Partners
Pune, India, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Glioma is a condition that covers a broad category of brain and spinal cord tumors that concern the glial cells in the brain function and can be fatal...
RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
15 nov. 2022 06h00 HE
|
RadioMedix Inc.
Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory...
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
07 oct. 2022 08h00 HE
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
26 juil. 2022 07h30 HE
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
19 oct. 2021 18h12 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
17 août 2021 09h25 HE
|
Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
13 janv. 2021 08h30 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...